Open-Label Extension Study of Marstacimab: Pfizer Has Reported a Fatal Event
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Safety Signal: Perioperative management with anti-TFPI therapy!
Pfizer has reported a fatal event in the open-label extension study of marstacimab (B7841007). The participant (haemophilia A with inhibitors) passed away on Dec 14 following a cerebellar infarction and cerebral haemorrhage.
What was the clinical context?
The event occurred perioperatively during minor surgery. The patient was receiving marstacimab prophylaxis + recombinant Factor VIIa (rFVIIa).
The Challenge
As we advance rebalancing therapies (anti-TFPI), this underscores the critical physiological threshold of thrombin generation. The synergy between TFPI inhibition and bypassing agents—particularly in surgical contexts—remains a complex therapeutic balance.
Status
While marstacimab is approved in the EU for non-inhibitor patients with haemophilia A and B, this event in the inhibitor cohort has triggered an immediate review of surgical management protocols by regulators and the DMC.
Full adjudication to better understand the safety margins and risk mitigation is needed for these novel agents.”
Title: WFH and NBDF statement on severe adverse event with marstacimab rebalancing agent for hemophilia
Read the full paper here.
Stay updated on all scientific advances from Wolfgang Miesbach with Hemostasis Today.
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge
-
Oct 19, 2026, 16:13Javier M. Floren: When Immune Cells Move With Their Environment